"ADAMTS13 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An ADAMTS protease that contains eight thrombospondin (TS) motifs. It cleaves VON WILLEBRAND FACTOR to control vWF-mediated THROMBOSIS. Mutations in the ADAMTS13 gene have been identified in familial cases of PURPURA, THROMBOTIC THROMBOCYTOPENIC and defects in ADAMTS13 activity are associated with MYOCARDIAL INFARCTION; BRAIN ISCHEMIA; PRE-ECLAMPSIA; and MALARIA.
| Descriptor ID |
D000071120
|
| MeSH Number(s) |
D08.811.277.656.675.374.102.500.813 D09.400.430.500.500.813 D12.776.395.033.500.813 D12.776.860.300.085.813
|
| Concept/Terms |
ADAMTS13 Protein- ADAMTS13 Protein
- von Willebrand Factor-Cleaving Protease
- von Willebrand Factor Cleaving Protease
- ADAMTS13 Protease
- vWF-Cleaving Protease
- vWF Cleaving Protease
- ADAMTS-13 Protein
- ADAMTS 13 Protein
- A Disintegrin and Metalloproteinase with Thrombospondin Motifs 13 Protein
|
Below are MeSH descriptors whose meaning is more general than "ADAMTS13 Protein".
Below are MeSH descriptors whose meaning is more specific than "ADAMTS13 Protein".
This graph shows the total number of publications written about "ADAMTS13 Protein" by people in this website by year, and whether "ADAMTS13 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2012 | 0 | 2 | 2 |
| 2017 | 6 | 5 | 11 |
| 2018 | 8 | 5 | 13 |
| 2019 | 3 | 0 | 3 |
| 2020 | 4 | 0 | 4 |
| 2021 | 6 | 3 | 9 |
| 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "ADAMTS13 Protein" by people in Profiles.
-
Distinctive Biomarker Features in the Endotheliopathy of COVID-19 and Septic Syndromes. Shock. 2022 01 01; 57(1):95-105.
-
A mild deficiency of ADAMTS13 is associated with severity in COVID-19: comparison of the coagulation profile in critically and noncritically ill patients. Blood Coagul Fibrinolysis. 2021 Oct 01; 32(7):458-467.
-
Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients. J Thromb Haemost. 2021 09; 19(9):2193-2198.
-
Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine. Int J Hematol. 2021 Nov; 114(5):626-629.
-
Acquired thrombotic thrombocytopenic purpura: A rare disease associated with BNT162b2 vaccine. J Thromb Haemost. 2021 09; 19(9):2314-2317.
-
First report of a de novo iTTP episode associated with an mRNA-based anti-COVID-19 vaccination. J Thromb Haemost. 2021 08; 19(8):2014-2018.
-
ADAMTS13 regulation of VWF multimer distribution in severe COVID-19. J Thromb Haemost. 2021 08; 19(8):1914-1921.
-
Vascular activation is a strong predictor of mortality in coronavirus disease 2019 patients on the ICU. Blood Coagul Fibrinolysis. 2021 Jun 01; 32(4):290-293.
-
Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. Blood Coagul Fibrinolysis. 2021 Jun 01; 32(4):285-289.
-
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond. Am J Hematol. 2021 08 01; 96(8):1049-1055.